MANCHESTER, England--(BUSINESS WIRE)--Mild cognitive impairment (MCI) is under the pharma’ spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.
